Is the NefIgArd trial a paradigm shift in the treatment of IgA nephropathy?

Affiliations

¹ Nephrology Department, University Hospital "12 de Octubre", Madrid, Spain.
² Nephrology Department, Research Institute "Hospital 12 de Octubre" (imas12), Madrid, Spain. Electronic address: fcaravacaf@gmail.com.

Comment

Eduardo Gutiérrez et al. Kidney Int. 2023 May.

. 2023 May;103(5):994.

doi: 10.1016/j.kint.2023.02.011.

¹ Nephrology Department, University Hospital "12 de Octubre", Madrid, Spain.
² Nephrology Department, Research Institute "Hospital 12 de Octubre" (imas12), Madrid, Spain. Electronic address: fcaravacaf@gmail.com.

No abstract available

Comment in

The authors reply.
Barratt J, Rovin BH; NefIgArd Investigators. Barratt J, et al. Kidney Int. 2023 May;103(5):994-995. doi: 10.1016/j.kint.2023.02.014. Kidney Int. 2023. PMID: 37085260 No abstract available.

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Clinical Trial.